Cargando…

PARP1-MGMT complex underpins pathway crosstalk in O(6)-methylguanine repair

DNA lesions induced by alkylating agents are repaired by two canonical mechanisms, base excision repair dependent on poly(ADP) ribose polymerase 1 (PARP1) and the other mediated by O(6)-methylguanine (O(6)meG)-DNA methyltransferase (MGMT) in a single-step catalysis of alkyl-group removal. O(6)meG is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cropper, Jodie D., Alimbetov, Dauren S., Brown, Kevin T. G., Likhotvorik, Rostislav I., Robles, Andrew J., Guerra, James T., He, Boxue, Chen, Yidong, Kwon, Youngho, Kurmasheva, Raushan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563463/ https://www.ncbi.nlm.nih.gov/pubmed/36242092 http://dx.doi.org/10.1186/s13045-022-01367-4

Ejemplares similares

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)

PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O(6)-methylguanine DNA damage in glioblastoma
por: Wu, Shaofang, et al.
Publicado: (2021)

Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine
por: Nilov, Dmitry, et al.
Publicado: (2020)

O(6)‐Methylguanine‐DNA Methyltransferase (MGMT) as a Determinant of Resistance to Camptothecin Derivatives
por: Okamoto, Ryo, et al.
Publicado: (2002)

O(6)-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy
por: Yu, Wei, et al.
Publicado: (2020)

O(6)-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
por: Kreth, Simone, et al.
Publicado: (2011)

O6-methylguanine-DNA methyltransferase (MGMT) Promoter methylation is a rare event in soft tissue sarcoma
por: Jakob, Jens, et al.
Publicado: (2012)

The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine
por: Cannella, Lucia, et al.
Publicado: (2023)

The role of direct DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) in high grade malignant glioma
por: Manoj, M Jeru, et al.
Publicado: (2014)

Immunohistochemical Assessment of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and Its Relationship with p53 Expression in Endometrial Cancers
por: Lee, Kyung Eun
Publicado: (2013)

Determining methylation status of methylguanine DNA methyl transferase (MGMT) from formalin-fixed, paraffin embedded tumor tissue
por: de Abreu, Francine B., et al.
Publicado: (2014)

Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience
por: Baur, Martina, et al.
Publicado: (2010)

Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo
por: Chen, Thomas C., et al.
Publicado: (2018)

O(6)-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma
por: Bobola, Michael S., et al.
Publicado: (2014)

Changes of O(6)-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse—A Meta-Analysis Type Literature Review
por: Feldheim, Jonas, et al.
Publicado: (2019)

The O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and clinical outcomes of Ewing sarcoma patients treated with irinotecan and temozolomide
por: Salah, Samer, et al.
Publicado: (2022)

Novel synthesis of O(6)-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O(6)-methylguanine DNA methyltransferase (MGMT)
por: Shibata, Takayuki, et al.
Publicado: (2006)

Genetic and environmental determinants of O(6)-methylguanine DNA-methyltransferase (MGMT) gene methylation: a 10-year longitudinal study of Danish twins
por: Wang, Lijie, et al.
Publicado: (2021)

Correcting inaccurate assumptions underpinning Transforming Care in England
por: O'Hara, Jean
Publicado: (2019)

O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions
por: Villalva, Claire, et al.
Publicado: (2012)

New insights into estrogenic regulation of O(6)-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: Co-degradation of ER-α and MGMT proteins by fulvestrant or O(6)-benzylguanine indicates fresh avenues for therapy
por: Paranjpe, Ameya, et al.
Publicado: (2016)

Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis
por: Markouli, Mariam, et al.
Publicado: (2022)

Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
por: Alimbetov, Dauren, et al.
Publicado: (2018)

Diffusion Kurtosis Imaging Reflects Glial Fibrillary Acidic Protein (GFAP), Topo IIα, and O(6)-Methylguanine-DNA Methyltransferase (MGMT) Expression in Astrocytomas
por: Wang, Xiao-chun, et al.
Publicado: (2018)

Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)(+) Glioblastoma Cells in a Snail-1/Cx43-Dependent Manner
por: Kochanowski, Paweł, et al.
Publicado: (2021)

Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
por: Hiddinga, Birgitta, et al.
Publicado: (2022)

S-phase Specific Downregulation of Human O(6)-Methylguanine DNA Methyltransferase (MGMT) and its Serendipitous Interactions with PCNA and p21(cip1) Proteins in Glioma Cells
por: Mostofa, AGM, et al.
Publicado: (2018)

Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing
por: Ghilu, Samson, et al.
Publicado: (2021)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation
por: Geier, Brian, et al.
Publicado: (2015)

A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells
por: Senhaji Mouhri, Zhor, et al.
Publicado: (2017)

Recent Developments in Nanomedicine for Pediatric Cancer
por: Yang, Shicheng, et al.
Publicado: (2021)

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation
por: Marranci, Andrea, et al.
Publicado: (2023)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism
por: Luna, Augustin, et al.
Publicado: (2013)

Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
por: Liposits, G., et al.
Publicado: (2021)

RAD51AP1 mediates RAD51 activity through nucleosome interaction
por: Pires, Elena, et al.
Publicado: (2021)

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
por: Del Pozo, Vanessa, et al.
Publicado: (2021)

Monkeypox virus crosstalk with HIV; where do we stand now?
por: Shafaati, Maryam, et al.
Publicado: (2022)

Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series
por: Oliveira, Jennifer L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vjiblpsf39gth6ot3f656i4h88